Key opinion leaders discuss strategies for managing neurotoxicity with lorlatinib and other ALK inhibitors, including monitoring adverse events and balancing symptom management with treatment efficacy ...

Key opinion leaders examine approaches to managing skin-related side effects, such as rash, in patients on EGFR inhibitors, ...

Several new treatment options for patients with breast cancer have emerged over the last few years, including more oral ...

The addition of trastuzumab and pertuzumab to chemotherapy was associated with increased toxicity in patients with ...

ctDNA Status May Be Prognostic for DFS With Celecoxib for Stage III Resected Colon Cancer ...

ctDNA Status May Be Prognostic for DFS With Celecoxib for Stage III Resected Colon Cancer ...

BC, CNM, RNFA, spoke about the oncology nurse’s and APP’s roles in managing chemotherapy-induced peripheral neuropathy in ...

Managing weight loss with telotristat ethyl in patients with metastatic pancreatic ductal adenocarcinoma may improve survival ...

ctDNA Status May Be Prognostic for DFS With Celecoxib for Stage III Resected Colon Cancer ...

ctDNA Status May Be Prognostic for DFS With Celecoxib for Stage III Resected Colon Cancer ...